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Background -A study was undertaken to test the hypothesis that a particular inhaled P agonist, fenoterol, increases the incidence of severe life threatening asthma. Methods -A retrospective cohort was assembled comprising 655 patients with asthma aged years who attended a single Auckland hospital for acute asthma between 1 January 1986 and 31 December 1987 (the "index event"). Patients were followed for the occurrence of death from asthma or admission to the intensive care unit for asthma, until death or 31 May 1989. Data on asthma medications and asthma severity were obtained from forms used specifically for managing patients with acute asthma in the emergency department and maintained as part of the hospital record and/or from the hospital record (when patients were admitted). Results -Following the index event 90 admissions to the intensive care unit (ICU) and 15 asthma deaths were identified. Before adjusting for asthma severity, patients using inhaled fenoterol had a greater incidence of severe life threatening asthma than patients using inhaled salbutamol (RR=2.1, 95% CI 1.4 to 3.1). After controlling for two markers of severe asthma used in previous studies -a hospital admission in the previous year and prescribed oral corticosteroids -the relative risk estimate declined to 1.5 (95% CI 1.0 to 2.3). After controlling further for the number of hospital admissions during the study period, continuous oral corticosteroid use rather than short courses of treatment, severity of the previous attack requiring a hospital visit, and race, fenoterol was not associated with severe life threatening asthma at the time of attendance for a previous hospital visit (RR= 1.0, 95% CI 0.6Ato 1.7) .
Conclusion -Fenoterol is used more often by patients with severe asthma and, after adjusting for differences in baseline risk, it does not increase the risk of severe life threatening asthma.
(Thorax 1996;51:1093-1099) Keywords : severe life threatening asthma, fenoterol, confounding by severity.
Fenoterol, a ,B agonist used to treat acute asthma, was introduced in New Zealand in 1976. In 1989 a case-control study from Wellington reported that fenoterol was associated with an increased risk of death from asthma.' Fenoterol (200 jig/puff) was the newest [3 agonist on the market and was introduced as a drug with a longer duration of action than the then most popular drug, salbutamol (100 jig/puff).
If fenoterol was prescribed preferentially to patients whose asthma was not controlled with existing medications, and baseline risk was not adequately measured and controlled in an epidemiological study, fenoterol would appear to be associated with a poor prognosis even if it were as safe and effective as other inhaled [B agonists . A small amount of bias due to confounding by asthma severity was demonstrated in a previous study conducted in Wellington in which adjustment for two markers of severity (a hospital admission in the previous year and a prescription for oral steroids at the time of a previous hospital admission) reduced the relative risk (RR) estimate for death associated with inhaled fenoterol from 2.7 to 2.3.2" More recently, a study of asthma death and near death conducted in Saskatchewan, Canada also showed that adjustment for recent hospital admissions and any use of oral steroids reduced the estimate of the rate difference for fenoterol by 36%, from 56.3/10 000 personyears to 36.2/10 000 person-years.4 In both the Wellington and Saskatchewan studies, therefore, adjustment for two markers of asthma severity reduced the magnitude of the association between fenoterol and asthma death. Debate has focused on whether or not residual confounding could explain the association.25-8
To help determine whether fenoterol increases the risk of life threatening asthma or whether the association can be explained by preferential prescribing of fenoterol to patients with severe asthma we conducted a retrospective cohort study for which data on drug use and asthma severity were obtained in greater completeness and detail than was available in previous studies.
In characterising severity by use of oral corticosteroids, previous studies' 24910 made no distinction between patients who receive a short course of oral corticosteroids in response to an acute exacerbation and those with chronically severe asthma who require continuous oral corticosteroids. In addition, measures of acute severity at the time of the patient's previous hospital admission were often not recorded within the hospital records. We wondered what the effect would be of measuring and controlling for these variables.
Methods
In 1986 a system was introduced at Middlemore Hospital in South Auckland (population 310 000) whereby Emergency Department medical staff assessed and managed patients with asthma according to a protocol stipulating that certain data on medications and severity be recorded on a specially designed triplicated form. These forms and regular hospital records were used to identify all residents of South Auckland aged 15-55 years who presented to the emergency department with an attack of asthma between 1 January 1986 and 31 December 1987, whether they required admission or not (the "index event"; fig 1) . Older patients were excluded because of a greater likelihood that their drugs were prescribed for conditions other than asthma -for example, chronic obstructive pulmonary disease -and younger patients were excluded because they would have been admitted to a paediatric hospital in central Auckland.
Patients were followed for the occurrence of a severe life threatening attack which we defined as an admission to the intensive care unit for asthma or asthma death, until death or 31 May 1989 (the approximate date of publication of the first case-control study on fenoterol), whichever came first. Patients admitted to an intensive care unit in Auckland with asthma are seriously ill, with a mean pH of 7.1 and a mean Paco2 of 10kPa."1 Other hospital admissions or visits to the emergency department for asthma were also identified as they provided information on severity markers and drug use. In every instance patients presenting at hospital for asthma in South Auckland are assessed in the emergency department before a decision is made regarding need for admission. Use of the emergency department was assessed by searching the records at the hospital from which patients were recruited. Computer files of the National Health Statistics Centre (and the locally maintained database) were used to validate regional hospital admissions and to identify any admissions outside the region and deaths. Admissions to the intensive care unit were identified using computer records of the two regional units and these files were checked against paper records.
Information on the use of asthma drugs and disease severity was Person time was accrued from the discharge date for the index hospital visit until death or end of study. Each patient was classified according to demographic data, asthma drugs, and indices of acute and chronic severity at the time of the index hospital visit. Patients were reclassified for any subsequent hospital visits. Thus, patients were classified according to asthma drugs prescribed and the severity of their asthma at the time of discharge from their previous hospital visit until a subsequent hospital visit or until the end of follow up. The only exception was for the use of oral corticosteroids which was characterised at the time of admission at the previous hospital attendance (as it was in previous studies). To avoid adjusting for a possible adverse effect of fenoterol after admission to hospital, asthma severity was classified at the time ofthe previous hospital visit, and not at the outcome event. This allowed control for baseline risk and allowed for the measurement of the subsequent effect of fenoterol.
Incidence rates for severe life threatening asthma were computed as the total number of events divided by the person time contributed by each subject from the index event until the date of death or the end of the follow up period on 31 The number ofterms in the multivariate models was limited when corresponding stratified analyses revealed sparse data.'3 Logistic regression was used to examine the odds of being prescribed fenoterol among patients of different severity, and the width of the 95% confidence intervals was used to assess the precision of the effect estimates. '2 All of the data for this study were recorded before the publication of the first report of an association between fenoterol and asthma death. The research assistants performing the data extraction were blinded as to the precise hypothesis under study.
Results

PATIENT CHARACTERISTICS
A total of 655 patients with asthma were identified who fulfilled the entry criteria (a further 51 patients resided outside South Auckland and in 19 patients the data were not sufficiently complete to be recruited (demographic data missing or triplicated emergency department form not used)). These 655 subjects contributed 1571 person years to the analysis. The distribution of the study population at entry according to age, sex, race, and type of index event was similar to data from a prospective study on emergency department care at Middlemore Hospital'4 15; the population was young (56% of patients less than 30 years of age) and predominantly female (64%). The racial distribution was 44% European, 29% Pacific Islander, 26% Maori, and 1% were classified as "other" or for whom information on race was missing. Most of the index events (59%) were visits to the emergency department, while the remainder were hospital admissions including 47 (7%) to the intensive care unit.
There were 105 subsequent severe life threatening attacks among 66 patients comprising 90 admissions to the intensive care unit and 15 asthma deaths. Four of the deaths occurred shortly after admission (two were receiving cardiopulmonary resuscitation on arrival). Independent of these severe life threatening attacks, there were 333 other hospital admissions and 520 emergency department visits not requiring admission (fig 1) .
DRUG THERAPY
The distribution of patients according to asthma drugs used at any time during the study For example, use of at least three classes of asthma drugs has the largest RR estimate, but only one case of severe life threatening asthma was not using at least three kinds of asthma drugs and the confidence interval is extremely wide (95% CI 6 to 629).
To introduce confounding bias, severity markers must be associated not only with the risk of severe life threatening asthma but also with the type of [2 agonist prescribed. Table 3 shows the odds ratios for prescribing fenoterol in relation to the number of prior hospital admissions and the type of course of oral corticosteroids. The odds ratio for receiving fenoterol among patients with multiple admissions during the study relative to patients with no prior admissions is 2.9 (95% CI 2.4 to 3.5).The odds ratio for receiving fenoterol among patients on continuous oral corticosteroids relative to patients who did not receive oral corticosteroids following a hospital visit is 1.9 (95% CI 1.2 to 2.8).
CONTROLLING FOR SEVERITY Table 4 shows RR estimates for severe life threatening asthma comparing users of inhaled ( as opposed to any versus none), and continuous use of oral corticosteroids (as opposed to any use), the RR estimate decreases further to 1.3 (95% CI 0.8 to 1.9). Finally, after controlling for number of hospital admissions during the study period, continuous use of oral corticosteroids, inability to speak at the previous hospital visit, and race, the RR estimate is 1.0 (95% CI 0.6 to 1.7). The rationale in constructing this model is that admission in the past year and any oral steroid course have been reported previously as good severity markers and were also found to be consistently important in a range of sensitivity analyses that we conducted using different combinations of confounding variables. Inability to speak was selected because of its strong association with severe life threatening asthma and because there were limited missing data compared with other severity markers (24% person time was excluded due to missing data), and race was included because, unlike other variables, controlling for this factor tended to increase the RR for fenoterol. Therefore, by choosing these four risk factors we have utilised the best measurements of acute severity (inability to speak), chronic severity (continuous steroid use), morbidity (previous hospital admissions), and sociodemographic characteristics (race).
Controlling individually for each variable from table 2 revealed that, when comparing users of inhaled fenoterol with those of inhaled salbutamol, control for nearly every variable (apart from race) decreased the RR estimates for severe life threatening asthma. The greatest reductions in the RR estimate occurred when controlling for markers of severity, but these variables were not available for all subjects. In particular, data on arterial Paco, were available for only 36% and data on compliance in only 24% of the records. This issue was addressed in two ways: (1) by including in the analysis all variables and excluding records with missing data, and (2) by excluding variables which had missing data. The specific confounding variables included in the final analysis were selected from the change in estimate criterion and stepwise procedures (both procedures yielding virtually identical results). Stepwise selection procedures using all variables as potential confounding variables controlling for admission in the past year, any oral steroid (tapering or continuous) course, and physician assessment of severity of previous acute attack yielded RR=0 .90 (95% CI 0.41 to 2.0). To gauge the potential impact of incomplete data for severity markers, the markers of clinical severity for which 17-35% of the person time was coded as missing were removed. Stepwise procedures on this limited data set controlled for the number of previous admissions during the study period, admissions in the past year, and any oral steroid (tapering or continuous) course, and produced an RR of 1.2 (95% CI 0.82 to 1.9) . This procedure eliminates the problem of missing data but also prevents us from controlling for severity markers that appear to be related to both fenoterol and severe life threatening asthma but for which in- 
Discussion
This study confirms previous research showing that, before adjusting for baseline risk, inhaled fenoterol is associated with an increased risk of severe life threatening asthma compared with inhaled salbutamol (RR 2.1), and that adjustment for a hospital admission in the past year and any use of oral corticosteroids at the time of the previous attendance reduces the association for inhaled fenoterol (RR 1.5) but does not eliminate it.2A10 The initial analysis of the Saskatchewan study found that the RR estimate for fenoterol increased after adjustment for asthma severity,'6 but after a more appropriate statistical model was employed in the analysis the effect estimate for fenoterol declined markedly. 4 The results reported here differ from previous work in that, after taking into account additional or more specific detailed classification of risk factors including acute severity at the previous hospital visit (as measured by an inability to speak), race, use of continuous oral corticosteroids at the previous hospital visit (as opposed to any use), and the total number ofprevious admissions during the study (as opposed to admissions in the past year), inhaled fenoterol was not associated with an increased risk of severe life threatening asthma. The association between inhaled fenoterol and severe life threatening asthma in this study therefore appears to be explained by fenoterol being prescribed preferentially to patients with severe asthma. Confounding bias could arise only ifvariables that were related to the risk of severe life threatening asthma independently from fenoterol were also strongly related to the likelihood of being prescribed fenoterol. We found that use of oral corticosteroids (particularly continuous use) and previous hospital admissions (particularly multiple admissions) are associated not only with an increased risk of severe life threatening asthma (table 2) , but also with an increased likelihood of being prescribed fenoterol (table 3) . This finding supports the contention that fenoterol was channelled to severe patients, as reported previously in the Netherlands'7 and New Zealand.819
It could be argued that the reason patients using fenoterol appeared to have more severe asthma is because fenoterol caused the asthma to become more severe. Therefore, by controlling for baseline risk at the time of the previous event (hospital attendance) we were able to assess potential adverse effects of the prescription offenoterol. Fenoterol could have a different effect on asthma death than it has on admissions to the intensive care unit for asthma. It has been postulated that overuse of fenoterol during an attack of asthma severe enough to cause hypoxia may be associated with an increased risk of cardiac arrhythmia when compared with the more 32 selective inhalers such as salbutamol and terbutaline.2" Although it would have been ideal to analyse deaths and admissions to the intensive care unit separately, there were insufficient deaths to conduct conditional analyses that controlled for confounding. However, the unadjusted effect estimates for deaths and admissions to the intensive care unit were very similar. In addition, the researchers who conducted the first study of fenoterol and asthma death have recently reported that fenoterol is also associated with an approximate doubling in the risk of admission to the intensive care unit (RR= 2.0, 95 % CI 1.4 to 3.0), and that the RR estimate declined slightly after adjusting for a hospital admission in the past year, any oral corticosteroid use at the time of the previous admission, and oral theophylline (RR = 1.8, 95% CI 1.2 to 2.6)."' These results support previous findings of our research group that patients with an admission to the intensive care unit are similar both clinically and demographically to those who die," and that patients who have had a near fatal attack are a group defined as being at high risk of subsequent death.2' Thus, the association with fenoterol appears to be essentially the same for asthma death and life threatening asthma.
Despite the availability of much improved data on asthma severity when compared with previous studies, asthma severity and other risk factors for severe life threatening asthma could be measured more access to their medical records and Dr P Rodwell and Dr A Veale in particular who were instrumental in establishing the triplicated asthma management forms. This study was supported by the Asthma Foundation of New Zealand and a grantin-aid from Boehringer Ingelheim Ltd towards the data analysis.
